Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Braz. j. infect. dis ; 25(3): 101596, 2021. tab
Artigo em Inglês | LILACS | ID: biblio-1339422

RESUMO

ABSTRACT Brazil is a huge continental country with striking geographic differences which are well illustrated in the HIV/AIDS epidemic. Contrasting with the significant decline in the national AIDS detection rate in the last decade, a linear growth has been reported in the Northern region. Despite its public health and epidemiologic importance, there is scarce HIV-1 molecular data from Northern Brazil. This scoping review summarizes recent epidemiologic data with special emphasis on HIV-1 genetic diversity and antiretroviral drug resistance mutations in patients from the seven Northern states of Brazil. Studies from the Northern Brazil on different HIV-1 genomic regions, mostly pol (protease/reverse transcriptase) sequences of naïve/antiretroviral treated adults/children were retrieved from PubMed/MEDLINE electronic database. These studies indicate a consistent molecular profile largely dominated by HIV-1 subtype B with minor contribution of subtypes F1 and C and infrequent detection of other subtypes (A1, D, K), recombinants (BF1, BC), circulating recombinant forms (CRF) as the new CRF90_BF1 and CRF02_AG-like, CRF28-29_BF-like, CRF31_BC-like, and a potential new CRF_BF1. This pattern indicates a founder effect of subtype B and the introduction of non-B-subtypes and recombinants probably generated in the Southern/Southeastern regions. In naïve populations transmitted drug resistance (TDR) can impact the outcome of first-line antiretroviral treatment and prophylactic/preventive regimens. In the Northern region TDR rates are moderate while patients failing highly active antiretroviral therapy (HAART) showed high prevalence of acquired drug resistance mutations. The limited HIV-1 molecular data from Northern Brazil reflects the great challenges to generate comprehensive scientific data in isolated, underprivileged areas. It also highlights the need to invest in local capacity building which supported by adequate infrastructure and funding can promote robust research activities to help reduce the scientific asymmetries in the Northern region. Currently the impacts of the overwhelming COVID-19 pandemic on the expanding HIV/AIDS epidemic in Northern Brazil deserves to be closely monitored.


Assuntos
Humanos , Infecções por HIV/tratamento farmacológico , Infecções por HIV/epidemiologia , HIV-1/genética , COVID-19 , Filogenia , Brasil , Resistência a Medicamentos , Análise de Sequência de DNA , Farmacorresistência Viral/genética , Pandemias , SARS-CoV-2 , Genótipo , Mutação
2.
Korean Journal of Medicine ; : 235-236, 2007.
Artigo em Coreano | WPRIM | ID: wpr-96902

RESUMO

Antiretroviral therapy for treatment of human immunodeficiency virus type 1 (HIV-1) infection has improved steadily since the introduction of combination therapy in 1996. With the advancement of antiretroviral therapy, the mortality of AIDS patients has markedly improved. However, drug resistance has been emerging as a major problem in HIV treatment. Several studies reported that the prevalence of transmitted resistant virus involving antiretroviral-naive people in developed countries was around 10%. Primary drug resistance is rare in HIV-1 infected patients in Korea. A cohort study is need to monitor resistant HIV-1 among newly infected individuals.


Assuntos
Humanos , Estudos de Coortes , Países Desenvolvidos , Resistência a Medicamentos , HIV , HIV-1 , Coreia (Geográfico) , Mortalidade , Prevalência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA